Literature DB >> 7662169

The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface.

N Behrendt1, E Rønne, K Danø.   

Abstract

Proteolytic degradation processes, resulting from the activation of plasminogen by the specific enzyme, urokinase plasminogen activator (uPA), take place in the extracellular matrix during cancer invasion as well as in tissue remodelling under certain normal-physiological conditions. The uPA receptor, uPAR, is a cell-surface protein which plays an important role in the localization and regulation of these processes. In the present article a number of established conclusions concerning the structure and function of uPAR are presented, and in addition various models are discussed which might explain additional observations for which the mechanisms involved have not yet been clarified experimentally. uPAR is a highly glycosylated, 3-domain protein, anchored in the plasma membrane by a glycolipid moiety. The domain organization is important for efficient ligand-binding, and the NH2-terminal domain is directly involved in the molecular contact with uPA. The receptor binds uPA as well as its proenzyme, pro-uPA, in such a manner that the activation cascade can occur directly on the cell surface. Furthermore, the activation rates are enhanced relative to the situation in solution, probably due to an interplay between uPAR and other, unidentified components. In addition to the function in the regulation of proteolysis, uPAR seems to play a role in internalization processes and in cellular signal transduction and adhesion. A few reagents have been identified which are capable to inhibit the interaction between uPAR and uPA. The growing knowledge on the structure and function of uPAR which is a result of protein chemical analyses, functional studies and analyses of other, interacting components, should help to obtain a better understanding of the regulation of extracellular proteolysis. In conjunction with the continuous identification of inhibitory reagents, this knowledge should open the possibility to interfere with the resulting, degradative events.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7662169

Source DB:  PubMed          Journal:  Biol Chem Hoppe Seyler        ISSN: 0177-3593


  20 in total

Review 1.  LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies.

Authors:  Anna P Lillis; Lauren B Van Duyn; Joanne E Murphy-Ullrich; Dudley K Strickland
Journal:  Physiol Rev       Date:  2008-07       Impact factor: 37.312

Review 2.  Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity.

Authors:  Dudley K Strickland; Dianaly T Au; Patricia Cunfer; Selen C Muratoglu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-06       Impact factor: 8.311

Review 3.  Proteolytic networks in cancer.

Authors:  Steven D Mason; Johanna A Joyce
Journal:  Trends Cell Biol       Date:  2011-01-12       Impact factor: 20.808

4.  Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.

Authors:  A Poliakov; V Tkachuk; T Ovchinnikova; N Potapenko; S Bagryantsev; V Stepanova
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

Review 5.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

6.  Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.

Authors:  M Oberst; J Anders; B Xie; B Singh; M Ossandon; M Johnson; R B Dickson; C Y Lin
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 7.  Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate?

Authors:  S A DaCosta; L M Schumaker; M J Ellis
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

8.  Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.

Authors:  Andrew P Mazar; Richard W Ahn; Thomas V O'Halloran
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

9.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

10.  Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis.

Authors:  Mikhail Menshikov; Eugenia Elizarova; Karina Plakida; Angelika Timofeeva; Georgy Khaspekov; Robert Beabealashvilli; Alex Bobik; Vsevolod Tkachuk
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.